Drug Trial Radar · NCT03196297
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Last checked: Nov 20, 2026Latest source record: Nov 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Aug 16, 2017
Primary completion
Jun 22, 2018
Study completion Jun 3, 2020
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jun 22, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in patients with severe haemophilia A without inhibitors.
Conditions
- Haemostasis
- Haemophilia A
Interventions
ConcizumabDrug
0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase
Turoctocog alfaDrug
Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of Bleeding Episodes During at Least 24 Weeks From Treatment OnsetTime frame: During at least 24 weeks from treatment onset
Locations
31 sites in 11 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Los Angeles, California
Novo Nordisk Investigational Site
Indianapolis, Indiana
Novo Nordisk Investigational Site
Oklahoma City, Oklahoma
Novo Nordisk Investigational Site
Nashville, Tennessee
Novo Nordisk Investigational Site
Salt Lake City, Utah
Novo Nordisk Investigational Site
Brest, France
Novo Nordisk Investigational Site
Caen, France
Novo Nordisk Investigational Site
Nantes, France
Novo Nordisk Investigational Site
Bonn, Germany
Novo Nordisk Investigational Site
Homburg, Germany
Novo Nordisk Investigational Site
Milan, Italy
Novo Nordisk Investigational Site
Rome, Italy
Novo Nordisk Investigational Site
Aichi, Japan
Novo Nordisk Investigational Site
Nara, Japan
Novo Nordisk Investigational Site
Tokyo, Japan
Novo Nordisk Investigational Site
Tokyo, Japan
Novo Nordisk Investigational Site
Madrid, Spain
Novo Nordisk Investigational Site
Málaga, Spain
Novo Nordisk Investigational Site
Valencia, Spain
Novo Nordisk Investigational Site
Malmö, Sweden
Novo Nordisk Investigational Site
Solna, Sweden
Novo Nordisk Investigational Site
Bangkok, Thailand
Novo Nordisk Investigational Site
Ankara, Turkey (Türkiye)
Novo Nordisk Investigational Site
Bornova-IZMIR, Turkey (Türkiye)
Novo Nordisk Investigational Site
Edirne, Turkey (Türkiye)
Novo Nordisk Investigational Site
Istanbul, Turkey (Türkiye)
Novo Nordisk Investigational Site
Lviv, Ukraine
Novo Nordisk Investigational Site
Belfast, United Kingdom
Novo Nordisk Investigational Site
Cambridge, United Kingdom
Novo Nordisk Investigational Site
London, United Kingdom
Novo Nordisk Investigational Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.